Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Kymera Therapeutics reported that the FDA granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for treating moderate to severe eosinophilic asthma, while partner Gilead exercised its option to exclusively license Kymera-discovered CDK2 degrader KT-200, triggering a US$45,000,000 milestone payment. Together, the regulatory recognition for KT-621 and the expanded Gilead collaboration highlight external validation of Kymera’s protein degradation platform, spanning both Type 2 inflammatory disease and oncology-like applications.
Among recent announcements, Gilead exercising its option on KT-200 and paying a US$45,000,000 milestone is most relevant here, as it reinforces third party interest in Kymera’s degrader science at the same time KT-621 moves onto a faster regulatory path. Together, these developments may increase investor focus on upcoming KT-621 Phase 2b data and on Kymera’s ability to convert partnered programs into additional milestones if key studies progress as currently planned.
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its immunology programs target STAT6, IRF5 and IRAK4, and it is developing KT-621 as part of its STAT6 program.
Research and development expenditures rose to $74.1 million in the third quarter, indicating investment in advancing clinical trials, particularly for KT-621's Phase 2b study. Kymera Therapeutics' narrative projects $38.1 million revenue and $5.6 million earnings by 2029; this requires fairly flat yearly revenue growth and a $317.0 million earnings increase from -$311.4 million today.